Weaning Approaches for Vasopressin in Sepsis

Launched by HOSPITAL NOSSA SENHORA DA CONCEICAO · Jul 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the best way to stop a medicine called vasopressin in patients who have septic shock, a serious infection that affects the whole body and causes very low blood pressure. The study will compare two methods of stopping vasopressin: slowly lowering the dose over time (titrated reduction) versus stopping it all at once (abrupt withdrawal). The main goal is to see which method leads to fewer episodes of low blood pressure during this process.

Adults over 18 years old who are in the Intensive Care Unit (ICU) with septic shock and are currently receiving both vasopressin and another medicine called norepinephrine to support their blood pressure may be eligible to join. People whose vasopressin is being stopped because of a move to comfort care, or because they are starting other blood pressure medicines like adrenaline, won’t be able to participate. If you take part, you will be randomly assigned to one of the two ways of stopping vasopressin, and doctors will closely monitor your blood pressure to see how well you tolerate the change. This study is not yet recruiting participants but aims to help improve care for patients with septic shock in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 18 years
• • Admitted to the Intensive Care Unit
• • Patients with vasopressor dependent sepsis
• • Receiving combined norepinephrine and vasopressin therapy
• Exclusion Criteria:
• • Withdrawal/reduction of vasopressin related to a plan of treatment limitation or palliative care
• • Withdrawal/reduction of vasopressin associated with the initiation of adrenaline or any other vasopressor